Alveo and Royal GD Expanded Veterinary Diagnostic Pact
The partners have committed new R&D resources to develop molecular testing for respiratory diseases in swine and cattle.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you support prioritizing new diagnostic technology to improve livestock health and disease control?
Alveo Technologies and Royal GD have announced an expanded partnership to grow their global molecular diagnostic offerings. The companies are building on an existing three-year collaboration that includes an 18-month commercial deployment of an on-farm avian influenza test.
Why it matters
This expansion aims to provide agricultural producers with the capacity for earlier disease detection and faster control measures. By targeting swine and cattle, the firms are diversifying the application of their established molecular diagnostic platform.
The companies have utilized their diagnostic platform to support field-level avian influenza testing for 18 months. Development is now shifting to adapt these molecular detection methods for respiratory illnesses in cattle and swine populations.
The players
Alveo Technologies
A diagnostic company that develops molecular testing platforms for rapid on-site pathogen identification.
Royal GD
A veterinary diagnostic organization that provides laboratory services and animal health research to the agricultural sector.
The details
The collaboration leverages the Alveo platform to enable rapid molecular identification of pathogens outside of traditional laboratory settings. Royal GD will integrate its specialized research and development resources into this platform to calibrate tests for livestock-specific viruses. To support these deployments, Alveo is concurrently scaling its global distributor network to ensure localized technical and operational support for producers.
Timeline
September 2023 marked the beginning of the three-year collaboration.
March 2025 saw the start of the 18-month commercial deployment for avian influenza testing.
September 22, 2026, served as the formal announcement date of the expanded partnership.
The Tech Race
This partnership follows a broader industry trend toward accelerating disease detection via decentralized, molecular-grade field testing. It pits the Alveo platform against traditional lab-based diagnostics in the race to provide actionable veterinary health data to global producers.
Agricultural producers should expect increased accessibility to molecular diagnostic tools as the companies expand their global distributor network. The transition of these tests into swine and cattle markets will allow farmers to identify respiratory pathogens more quickly than current protocols permit.
The takeaway
The success of this collaboration will be measured by the speed at which the companies bring their planned swine and cattle diagnostics to market. Observers should monitor the expansion of Alveo's distribution network to see how effectively the firm delivers technical support for these new testing kits.
Further reading
For more on the current state of diagnostic innovation, see the Biotech section.
Live Poll
Do you support prioritizing new diagnostic technology to improve livestock health and disease control?
